ZIOPHARM ONCOLOGY INC License Agreements

9 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2022
Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2022
Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2022
Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2020
Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2020
Amendment to Patent License Agreement, dated as of January 8, 2020 , by and between the Company and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2020
Patent License Agreement, dated as of May 28, 2019, by and between the Company and the National Cancer Institute
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
2019
Exclusive License Agreement by and between the registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
NY
2018
LICENSE AGREEMENT
License Agreements
ZIOPHARM ONCOLOGY INC
Biotechnology
TX
2015